Phase 3 SPARTAN data served as basis for approval, which showed apalutamide decreased the risk of distant metastasis or death by 72 percent and improved median metastasis-free survival by more than two years

The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures, as an adjunctive therapy (given with another primary treatment) in patients 10 years and older who have responded inadequately to several alternative (refractory) treatments.

A Statement from the National Kidney Foundation (NKF)

New findings from an international research team led by psychiatrists at NYU School of Medicine show that a newly-developed analytic model can predict soon after a shocking or scary event – and with significant accuracy -- the likelihood of someone developing Post-Traumatic Stress Disorder (PTSD).

JDRF, formerly known as the Juvenile Diabetes Research Foundation, is advising adults living with diabetes of the benefits of inhaling insulin close to, or even during, meal times.

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations.

Ribon Therapeutics, a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions, announced the closing of a $65 million Series B financing. Proceeds will be used to advance lead programs from the company’s growing pipeline into clinical testing, including small molecule monoPARP inhibitors.

Risk greatest in people with later-stage cancers and lung and colon cancers

JHL Biotech announced that the first patient at Beijing Cancer Hospital has been successfully randomized in the Phase III study of JHL1101 to treat diffuse large B-cell lymphoma (DLBCL).

Compared to taking multiple injections daily, inhaled insulin can provide short-term benefits like controlling blood sugars after meal times.

MetTel is helping Rotech Healthcare Inc. to drive better patient care and personalization at healthcare facilities and at home through an innovative mobile initiative that has raised Rotech’s workforce productivity and doubled customer contact, both companies announced.

Nautilus Medical has announced delivery of their robust image management platform with all features to any medical professionals and students at no cost.

To Meet Burgeoning Need, RCA Adds a Third Center in New Jersey for Life-Saving Addiction Treatment Services

Leading Provider of Post-Acute Care Forms Component Patient Safety Organization

Research from the American Cancer Society shows lung cancer rates in Asian-Americans vary among subgroups.

Researchers from the University of California San Diego (UC San Diego) and its School of Medicine have completed a study that may help to better understand treatments and preventions for diseases affecting memory.

Updated Phase 3 ALCYONE results, featured as oral presentation at ASH 2018, show improved progression-free survival in newly diagnosed patients

Novartis announced longer-term analyses of both ELIANA and JULIET, the pivotal clinical trials of Kymriah (tisagenlecleucel) in children and young adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) and adult patients with r/r diffuse large B-cell lymphoma (DLBCL), respectively.

University of California (UC) San Diego Health has named San Diego Padres and San Diego Sea Lions soccer team physician Dr. Catherine Robertson as chief of sports medicine.

OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OBI-888 for the treatment of Pancreatic Cancer. OBI-888 is a first in class monoclonal antibody cancer immunotherapy targeting Globo H, a glycolipid antigen.